And (TaDa!!) here he is! Several websites and a few people here have claimed in the past that there's better durability from bovine (pericardial) than porcine, but I've never seen that documented in published studies. And the single tissue valve with the best documented durability in published studies seems to be "my" pig valve, the Medtronics Hancock II. There are several studies documenting that, most recently one from "my" center from 2010, entitled "Hancock II Bioprosthesis for Aortic Valve Replacement: The Gold Standard of Bioprosthetic Valves Durability?" by Tirone E. David, MD, Susan Armstrong, MS, Manjula Maganti, MS, in Ann Thorac Surg 2010;90:775-781, abstract at ats.ctsnetjournals.org/cgi/content/abstract/90/3/775? .
The end of the article (unfortunately not available in full-text online without paying ~$30, though I've "quoted" several key passages by retyping them into posts on this forum) compares their Hancock II "porcine" results with published results from a number of other tissue valves, including the CEPMagna cow (pericardial) valve. In summary, (a) the Hancock II durability figures are uniformly better than all the others, and (b) the authors explain that some of the other valve-durability publications use misleading measures, especially "freedom from explant" or "freedom from reop", rather than the more meaningful "freedom from structural valve deterioration". (If you're valve is deteriorating BUT you're too sickly to survive OHS, you are counted as a SUCCESS in terms of "freedom from explant" or "freedom from reop"!!)
Before we leave durability, it's important to note that newer valves may well have even better durability than "old standards" like the Hancock II and the CEPM, but they naturally can't prove it yet with actual statistics. The statistical proof that the Hancock II valve has ~20-plus-year durability in 65-plus-year-old patients is based on the analysis of 65-plus-year-old patients that received the valve ~20-plus years before the study was published. A valve developed and approved in 2005 can't demonstrate a successful ~20-plus-year track record, no matter how good it is, or will eventually be shown to be. So there's always going to be some tension between being "the first kid on the block" to get a valve that SEEMS to be better and SHOULD last longer, and getting an older, more established model whose durability has been proven and the proof published. (BTW, for mech valves, I personally believe that the various accelerated-aging tests are probably reasonable proof of the durability of the valve itself -- but I don't think there's any comparably credible proof of the durability of a new tissue valve.)
The other most-often-referenced component of the "best" tissue valve is usually hemodynamics. The idea here is that you'd like to be as far from stenosis post-op as possible, with as large and unobstructed a valve opening as possible, and as small a pressure drop across it as possible. On that scale, I've seen one published article (from 2007), directly comparing the CEPM cow/pericardial valve with the Hancock II pig valve --
http://ats.ctsnetjournals.org/cgi/content/full/83/6/2054#TBL3 -- and it finds that the CEPM has significantly better hemodynamics one week post-op. So, on the face of it, the pigs seem to win on durability, but the cows win on hemodynamics, specifically very early on.
Personal sidebar -- when I expressed disappointment with the (1.6 sq. cm.?) estimated effective area of my not-small (25 mm?) Hancock II from my post-op-discharge echo-cardiogram (~5 days post-op), my surgeon told me to wait for future echo-cardiograms, which would be better. And they have been (1 only, so far), though I don't have any numbers or reports here.
Secondly, I think the hemodynamics of a replacement AV, within reason, are probably irrelevant for the vast majority of patients -- the exceptions being those with "valve-donor mismatch", i.e., patients with unusually small AVs for the size of their bodies. The rest of us seem to be able to achieve high levels of athletic output and achievement relatively regardless of the measured area, flow rate, or pressure drop of our AVs. Indeed, most valve-replacement surgeons (including mine) have lots of stories about patients who competed in marathons and the like with valves that very soon afterwards astounded the surgeon with their terrible condition, and which also demonstrated high levels of stenosis on echo EKGs and other tests. My personal experience also fits in with that pattern, as I was in my 60s and easily keeping up with a bunch of 30-somethings in competitive volleyball (4-on-4 court and beach including 2-on-2!) with AV stenosis around .8 sq. cm., IIRC, and a valve that my surgeon said was "toast", among the worst he'd seen. My disappointing reading 5 days post-AVR had twice that effective area, so it's hard to believe it would hold ANYBODY back athletically, even if it never improved.
As ElectLive suggests above, it's also possible that a valve with better hemodynamics (a wider opening) will be a better candidate for TAVI, or for multiple TAVIs. It sounds logical, though logic doesn't always lead to proof in medicine.
Of course there are other considerations, too, e.g.: Any valve your surgeon is comfortable with is arguably a "better" valve than one that makes him/her nervous! In that regard, my fancy Toronto (Canada) center was an early adopter of the Hancock II, while most US centers seem to have gravitated toward the cow valves, for whatever reasons, good or bad. Even if the reasons don't seem compelling, a patient might reasonably choose a valve that puts your surgeon in the "comfort zone".